• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

瘦素降低是减肥的必要组成部分。

Leptin Reduction as a Required Component for Weight Loss.

机构信息

Touchstone Diabetes Center, The University of Texas Southwestern Medical Center, Dallas, TX.

Division of Endocrinology, Department of Medicine, University of Texas Health Science Center, San Antonio, TX.

出版信息

Diabetes. 2024 Feb 1;73(2):197-210. doi: 10.2337/db23-0571.

DOI:10.2337/db23-0571
PMID:37935033
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10796304/
Abstract

Partial leptin reduction can induce significant weight loss, while weight loss contributes to partial leptin reduction. The cause-and-effect relationship between leptin reduction and weight loss remains to be further elucidated. Here, we show that FGF21 and the glucagon-like peptide 1 receptor (GLP-1R) agonist liraglutide rapidly induced a reduction in leptin. This leptin reduction contributed to the beneficial effects of GLP-1R agonism in metabolic health, as transgenically maintaining leptin levels during treatment partially curtailed the beneficial effects seen with these agonists. Moreover, a higher degree of leptin reduction during treatment, induced by including a leptin neutralizing antibody with either FGF21 or liraglutide, synergistically induced greater weight loss and better glucose tolerance in diet-induced obese mice. Furthermore, upon cessation of either liraglutide or FGF21 treatment, the expected immediate weight regain was observed, associated with a rapid increase in circulating leptin levels. Prevention of this leptin surge with leptin neutralizing antibodies slowed down weight gain and preserved better glucose tolerance. Mechanistically, a significant reduction in leptin induced a higher degree of leptin sensitivity in hypothalamic neurons. Our observations support a model that postulates that a reduction of leptin levels is a necessary prerequisite for substantial weight loss, and partial leptin reduction is a viable strategy to treat obesity and its associated insulin resistance.

摘要

部分瘦素减少可引起显著的体重减轻,而体重减轻有助于部分瘦素减少。瘦素减少和体重减轻之间的因果关系仍有待进一步阐明。在这里,我们表明,成纤维细胞生长因子 21(FGF21)和胰高血糖素样肽 1 受体(GLP-1R)激动剂利拉鲁肽可迅速引起瘦素减少。这种瘦素减少有助于 GLP-1R 激动剂在代谢健康方面的有益作用,因为在治疗过程中转基因维持瘦素水平部分削弱了这些激动剂的有益作用。此外,用 FGF21 或利拉鲁肽结合瘦素中和抗体治疗时,可更显著地降低瘦素水平,从而在饮食诱导的肥胖小鼠中协同诱导更大的体重减轻和更好的葡萄糖耐量。此外,在停止使用利拉鲁肽或 FGF21 治疗后,观察到预期的即时体重反弹,同时循环瘦素水平迅速升高。用瘦素中和抗体预防这种瘦素激增可减缓体重增加并保持更好的葡萄糖耐量。从机制上讲,瘦素的显著减少导致下丘脑神经元的瘦素敏感性更高。我们的观察结果支持这样一种模型,即瘦素水平的降低是实质性体重减轻的必要前提,部分瘦素减少是治疗肥胖及其相关胰岛素抵抗的可行策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/14d8/10796304/2ea8f90fc383/db230571F0GA.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/14d8/10796304/2ea8f90fc383/db230571F0GA.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/14d8/10796304/2ea8f90fc383/db230571F0GA.jpg

相似文献

1
Leptin Reduction as a Required Component for Weight Loss.瘦素降低是减肥的必要组成部分。
Diabetes. 2024 Feb 1;73(2):197-210. doi: 10.2337/db23-0571.
2
The quantity, quality and findings of network meta-analyses evaluating the effectiveness of GLP-1 RAs for weight loss: a scoping review.评估胰高血糖素样肽-1受体激动剂(GLP-1 RAs)减肥效果的网状Meta分析的数量、质量及结果:一项范围综述
Health Technol Assess. 2025 Jun 25:1-73. doi: 10.3310/SKHT8119.
3
Preexisting Diabetes and Pregnancy: An Endocrine Society and European Society of Endocrinology Joint Clinical Practice Guideline.糖尿病合并妊娠:内分泌学会与欧洲内分泌学会联合临床实践指南
J Clin Endocrinol Metab. 2025 Jul 13. doi: 10.1210/clinem/dgaf288.
4
Preexisting Diabetes and Pregnancy: An Endocrine Society and European Society of Endocrinology Joint Clinical Practice Guideline.孕前糖尿病与妊娠:内分泌学会和欧洲内分泌学会联合临床实践指南
Eur J Endocrinol. 2025 Jun 30;193(1):G1-G48. doi: 10.1093/ejendo/lvaf116.
5
Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.二肽基肽酶(DPP)-4抑制剂和胰高血糖素样肽(GLP)-1类似物用于预防或延缓2型糖尿病高危人群发生2型糖尿病及其相关并发症。
Cochrane Database Syst Rev. 2017 May 10;5(5):CD012204. doi: 10.1002/14651858.CD012204.pub2.
6
A systematic review of GLP-1 on anthropometrics, metabolic and endocrine parameters in patients with PCOS.多囊卵巢综合征患者 GLP-1 对人体测量学、代谢和内分泌参数影响的系统评价
Womens Health (Lond). 2024 Jan-Dec;20:17455057241234530. doi: 10.1177/17455057241234530.
7
The Black Book of Psychotropic Dosing and Monitoring.《精神药物剂量与监测黑皮书》
Psychopharmacol Bull. 2024 Jul 8;54(3):8-59.
8
Mazdutide, a dual agonist targeting GLP-1R and GCGR, mitigates diabetes-associated cognitive dysfunction: mechanistic insights from multi-omics analysis.玛扎鲁肽,一种靶向胰高血糖素样肽-1受体(GLP-1R)和胰高血糖素受体(GCGR)的双重激动剂,可减轻糖尿病相关的认知功能障碍:多组学分析的机制见解
EBioMedicine. 2025 Jun 5;117:105791. doi: 10.1016/j.ebiom.2025.105791.
9
The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipron.奥佛吉朋对GLP-1受体的非肽激动作用的药理学基础。
Sci Transl Med. 2024 Dec 18;16(778):eadp5765. doi: 10.1126/scitranslmed.adp5765.
10
Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials.胰高血糖素样肽-1 受体激动剂对体重减轻的影响:随机对照试验的系统评价和荟萃分析。
BMJ. 2012 Jan 10;344:d7771. doi: 10.1136/bmj.d7771.

引用本文的文献

1
Affective-cognitive circuits in postoperative appetite reduction: an adaptive neuroimmune response to surgical stress.术后食欲减退中的情感-认知回路:对外科手术应激的适应性神经免疫反应。
Front Neurosci. 2025 Aug 12;19:1654559. doi: 10.3389/fnins.2025.1654559. eCollection 2025.
2
Comparing the influence of early and late time-restricted eating with energy restriction and energy restriction alone on cardiometabolic markers, metabolic hormones and appetite in adults with overweight/obesity: per-protocol analysis of a 3-month randomized clinical trial.比较早期和晚期限时进食联合能量限制与单纯能量限制对超重/肥胖成年人心脏代谢指标、代谢激素和食欲的影响:一项为期3个月的随机临床试验的符合方案分析。
Nutr Metab (Lond). 2025 Jul 29;22(1):85. doi: 10.1186/s12986-025-00984-3.
3

本文引用的文献

1
Rare Antagonistic Leptin Variants and Severe, Early-Onset Obesity.罕见的拮抗型瘦素变异与严重的早发性肥胖症。
N Engl J Med. 2023 Jun 15;388(24):2253-2261. doi: 10.1056/NEJMoa2204041.
2
The rheumatoid arthritis drug auranofin lowers leptin levels and exerts antidiabetic effects in obese mice.类风湿关节炎药物金诺芬可降低肥胖小鼠的瘦素水平并发挥抗糖尿病作用。
Cell Metab. 2022 Dec 6;34(12):1932-1946.e7. doi: 10.1016/j.cmet.2022.09.019. Epub 2022 Oct 14.
3
Activating Connexin43 gap junctions primes adipose tissue for therapeutic intervention.
The Effects of Adipose Tissue Dysregulation on Type 2 Diabetes Mellitus.脂肪组织调节异常对2型糖尿病的影响。
Biomedicines. 2025 Jul 19;13(7):1770. doi: 10.3390/biomedicines13071770.
4
Effects of Weight Loss on Endothelium and Vascular Homeostasis: Impact on Cardiovascular Risk.体重减轻对内皮及血管稳态的影响:对心血管风险的作用
Biomedicines. 2025 Feb 6;13(2):381. doi: 10.3390/biomedicines13020381.
5
Weight cycling exacerbates glucose intolerance and hepatic triglyceride storage in mice with a history of chronic high fat diet exposure.体重循环会加剧有慢性高脂饮食暴露史小鼠的葡萄糖不耐受和肝脏甘油三酯储存。
J Transl Med. 2025 Jan 4;23(1):7. doi: 10.1186/s12967-024-06039-0.
6
Regulation of energy balance by leptin as an adiposity signal and modulator of the reward system.瘦素作为肥胖信号和奖赏系统调节剂对能量平衡的调节。
Mol Metab. 2025 Jan;91:102078. doi: 10.1016/j.molmet.2024.102078. Epub 2024 Nov 29.
7
Adipokines: masterminds of metabolic inflammation.脂肪因子:代谢性炎症的幕后主使
Nat Rev Immunol. 2025 Apr;25(4):250-265. doi: 10.1038/s41577-024-01103-8. Epub 2024 Nov 7.
8
Evaluating Fibroblast Growth Factor 21 (FGF21) Levels Post-Gastric Sleeve Surgery in Obese Patients.评估肥胖患者胃袖状切除术后的成纤维细胞生长因子21(FGF21)水平。
Cureus. 2024 Aug 4;16(8):e66122. doi: 10.7759/cureus.66122. eCollection 2024 Aug.
9
Weight-loss maintenance is accompanied by interconnected alterations in circulating FGF21-adiponectin-leptin and bioactive sphingolipids.体重维持伴随着循环中FGF21-脂联素-瘦素和生物活性鞘脂的相互关联的变化。
Cell Rep Med. 2024 Jul 16;5(7):101629. doi: 10.1016/j.xcrm.2024.101629. Epub 2024 Jul 2.
激活连接蛋白43间隙连接可使脂肪组织做好治疗干预的准备。
Acta Pharm Sin B. 2022 Jul;12(7):3063-3072. doi: 10.1016/j.apsb.2022.02.020. Epub 2022 Feb 26.
4
A novel anti-obesity mechanism for liraglutide by improving adipose tissue leptin resistance in high-fat diet-fed obese mice.利拉鲁肽通过改善高脂肪饮食喂养肥胖小鼠的脂肪组织瘦素抵抗作用来发挥其新型抗肥胖机制。
Endocr J. 2022 Oct 28;69(10):1233-1244. doi: 10.1507/endocrj.EJ21-0802. Epub 2022 Jul 16.
5
Metreleptin for the treatment of lipodystrophy: leading the way among novel therapeutics for this unmet clinical need.米泊美生用于治疗脂肪代谢障碍:在满足这一未被满足的临床需求的新型疗法中处于领先地位。
Curr Med Res Opin. 2022 Jun;38(6):885-888. doi: 10.1080/03007995.2022.2059974. Epub 2022 Apr 12.
6
Why does obesity cause diabetes?肥胖为什么会导致糖尿病?
Cell Metab. 2022 Jan 4;34(1):11-20. doi: 10.1016/j.cmet.2021.12.012.
7
FGF21 ameliorates hepatic fibrosis by multiple mechanisms.成纤维细胞生长因子 21 通过多种机制改善肝纤维化。
Mol Biol Rep. 2021 Nov;48(11):7153-7163. doi: 10.1007/s11033-021-06707-0. Epub 2021 Sep 18.
8
Adiponectin preserves metabolic fitness during aging.脂联素在衰老过程中保持代谢健康。
Elife. 2021 Apr 27;10:e65108. doi: 10.7554/eLife.65108.
9
Adiponectin, Leptin and Cardiovascular Disorders.脂联素、瘦素与心血管疾病
Circ Res. 2021 Jan 8;128(1):136-149. doi: 10.1161/CIRCRESAHA.120.314458. Epub 2021 Jan 7.
10
Hyperleptinemia as a contributing factor for the impairment of glucose intolerance in obesity.高瘦素血症是导致肥胖患者葡萄糖耐量受损的一个因素。
FASEB J. 2021 Feb;35(2):e21216. doi: 10.1096/fj.202001147R. Epub 2020 Nov 23.